Production of biopharmaceuticals in E. Coli: Current scenario and future perspectives

Journal of Microbiology and Biotechnology

Volumn 25, Issue 7, 2015, Pages 953-962

  Baeshen, Mohammed N ^a   Al Hejin, Ahmed M ^a   Bora, Roop S ^a,b   Ahmed, Mohamed M M ^a,c   Ramadan, Hassan A I ^a,d   Saini, Kulvinder S ^a,b   Baeshen, Nabih A ^a   Redwan, Elrashdy M ^a,c  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^b ETERNAL UNIVERSITY   (India)

^c Universities and Research Institutes District   (Egypt)

^d NATIONAL RESEARCH CENTRE   (Egypt)

Author keywords

Biopharmaceuticals; Codon usage; E. coli; Molecular chaperones; Optimized protein production

Indexed keywords

BIOPHARMACEUTICAL; CHAPERONE; ESCHERICHIA COLI PROTEIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; BIOLOGICAL PRODUCT;

BACTERIAL STRAIN; BIOPROCESS; BIOTECHNOLOGY; CODON USAGE; ESCHERICHIA COLI; EXPRESSION VECTOR; GENE EXPRESSION SYSTEM; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN PROCESSING; REVIEW; SOLUBILITY; GENETICS; METABOLIC ENGINEERING; METABOLISM; PHARMACEUTICS; PROCEDURES; TRENDS;

ESCHERICHIA COLI;

BIOLOGICAL PRODUCTS; BIOTECHNOLOGY; ESCHERICHIA COLI; METABOLIC ENGINEERING; TECHNOLOGY, PHARMACEUTICAL;

EID: 84937411096     PISSN: 10177825     EISSN: 17388872     Source Type: Journal    
DOI: 10.4014/jmb.1412.12079     Document Type: Review

References (86)

1. Arya R, Sabir JSM, Bora RS, Saini KS. 2015. Optimization of culture parameters and novel strategies to improve protein solubility. In Insoluble Proteins: Methods and Protocols. Methods in Molecular Biology series, edited by Dr. Elena Garcia Fruitos, Vol. 1258, Chapter 3. Pages 45-63; Springer Science and Business Media, New York, USA.
2. Betiku E. 2006. Molecular chaperones involved in heterologous protein folding in Escherichia coli. Biotechnol. Mol. Biol. 1: 66-75
3. Brinkman U, Mattes RE, Buckel P. 1989. High-level expression of recombinant genes in Escherichia coli i s dependent on the availability of the dnaY gene product. Gene 85: 109-114
4. Calderone TL, Stevens RD, Oas TG. 1996. High-level misincorporation of lysine for arginine at AGA codons in a fusion protein expressed in Escherichia coli. J. Mol. Biol. 262: 407-412
5. Carrio MM, Villaverde A. 2003. Role of molecular chaperones in inclusion body formation. FEBS Lett. 537: 215-221
6. Chen R. 2012. Bacterial expression systems for recombinant protein production: E. coli and beyond. Biotechnol. Adv. 30: 1102-1107
7. Choi JH, Lee SY. 2004. Secretory and extracellular production of recombinant proteins using Escherichia coli. Appl. Microbiol. Biotechnol. 64: 625-635
8. Cuccui J, Wren B. 2015. Hijacking bacterial glycosylation for the production of glycoconjugates, from vaccines to humanised glycoproteins. J. Pharm. Pharmacol. 67: 338-350
9. Cui SS, Lin XZ, Shen JH. 2011. Effects of co-expression of molecular chaperones on heterologous soluble expression of the cold-active lipase Lip-948. Protein Expr. Purif. 77: 166-172
10. de Marco A. 2007. Protocol for preparing proteins with improved solubility by co-expressing with molecular chaperones in Escherichia coli. Nat. Protoc. 2: 2632-2639
11. De Smit MH, van Duin, J. 1990. Secondary structure of the ribosome binding site determines translational efficiency: a quantitative analysis. Proc. Natl. Acad. Sci. USA 87: 7668-7672
12. Dieci G, Bottarelli L, Ballabeni A, Ottonello S. 2000. Trna assisted overproduction of eukaryotic ribosomal proteins. Protein Expr. Purif. 18: 346-354
13. El-Baky NA, Redwan EM. 2015. Therapeutic alpha-interferons protein: structure, production, and biosimilar. Prep. Biochem. Biotechnol. 45: 109-127
14. Etchegaray JP, Inouye M. 1999. Translational enhancement by an element example of molecular misreading in Alzheimer’s disease. Trends Neurosci. 21: 331-335
15. Fahnert B, Lilie H, Neubauer P. 2004. Inclusion bodies: formation and utilization. Adv. Biochem. Eng. Biotechnol. 89: 93-142
16. Feng Y, Xu Q, Yang T, Sun E, Li J, Shi D, Wu D. 2014. A novel self-cleavage system for production of soluble recombinant protein in Escherichia coli. Protein Expr. Purif. 99: 64-69
17. Ferrer-Miralles N, Villaverde A. 2013. Bacterial cell factories for recombinant protein production; expanding the catalogue. Microb. Cell Fact. 12: 113
18. Fisher AC, Haitjema CH, Guarino C, Celik E, Endicott CE, Reading CA, et al. 2011. Production of secretory and extracellular N-linked glycoproteins in Escherichia coli. Appl. Environ. Microbiol. 77: 871-881
19. Folwarczna J, Moravec T, Plchova H, Hoffmeisterova H, Cerovska N. 2012. Efficient expression of human papillomavirus 16 E7 oncoprotein fused to C-terminus of tobacco mosaic virus (TMV) coat protein using molecular chaperones in Escherichia coli. Protein Expr. Purif. 85: 152-157
20. Guzzo J. 2012. Biotechnical applications of small heat shock proteins from bacteria. Int. J. Biochem. Cell Biol. 44: 1698-1705
21. Ihssen J , Kowarik M, Dilettoso S, Tanner C, Wacker M, Thöny-Meyer L. 2010. Production of glycoprotein vaccines in Escherichia coli. Microb. Cell Fact. 11: 9: 61
22. Iost I, Dreyfus M. 1994. Mrnas can be stabilized by DEADbox proteins. Nature 372: 193-196
23. Iost I, Bizebard T, Dreyfus M. 2013. Functions of DEAD-box proteins in bacteria: current knowledge and pending questions. Biochim. Biophys. Acta 1829: 866-877
24. Jensen EB, Carlsen S. 1990. Production of recombinant human growth hormone in Escherichia coli: expression of different precursors and physiological effects of glucose, acetate and salts. Biotechnol. Bioeng. 36: 1-11
25. Jenkins N. 2007. Modifications of therapeutic proteins: challenges and prospects. Cytotechnology 53: 121-125
26. Jeong W, Shin HC. 1998. Supply of the ArgU gene product allows high-level expression of recombinant human interferonalpha-2a in Escherichia coli. Biotechnol. Lett. 20: 19-22
27. Jhamb K, Sahoo DK. 2012. Production of soluble recombinant proteins in Escherichia coli: effects of process conditions and chaperone co-expression on cell growth and production of xylanase. Bioresour. Technol. 123: 135-143
28. Joly JC, Leung WS, Swartz JR. 1998. Overexpression of Escherichia coli oxidoreductases increases recombinant insulinlike growth factor-I accumulation. Proc. Natl. Acad. Sci. USA 95: 2773-2777
29. Jung ST, Kang TH, Kelton W, Georgiou G. 2011. Bypassing glycosylation: engineering aglycosylated full-length IgG antibodies for human therapy. Curr. Opin. Biotechnol. 22: 858-867
30. Kane JF, Violand BN, Curran DF, Staten NR, Duffin KL, Bogosian G. 1992. Novel in-frame two codon translational hop during synthesis of bovine placental lactogen in a recombinant strain of Escherichia coli. Nucleic Acids Res. 20: 6707-6712
31. Kane JF. 1995. Effects of rare codon clusters on high-level expression of heterologous proteins in Escherichia coli. Curr. Opin. Biotechnol. 6: 494-500
32. Khattar SK, Kundu PK, Gulati P, Singh V, Bughani U, Bajpaim M, Saini KS 2007. Optimization and enhanced soluble production of biologically active recombinant human p38 mitogen-activated-protein kinase (MAPK) in Escherichia coli. Protein Peptide Lett. 14: 756-760
33. Kim R, Sandler SJ, Goldman S, Yokota H, Clark AJ, Kim SH. 1998. Overexpression of archaeal proteins in Escherichia coli. Biotechnol. Lett. 20: 207-210
34. Kolaj O, Spada S, Robin S, Wall JG. 2009. Use of folding modulators to improve heterologous protein production in Escherichia coli. Microb. Cell Fact. 8: 9
35. Laursen BS, Sorensen HP, Mortensen KK, Sperling-Petersen HU. 2005. Initiation of protein synthesis in bacteria. Microbiol. Mol. Biol. Rev. 69: 101-123
36. Lebendiker M, Danieli T. 2014. Production of prone-toaggregate proteins. FEBS Lett. 588: 236-246
37. Lee YJ, Lee DH, Jeong KJ. 2014. Enhanced production of human full-length immunoglobulin G1 in the periplasm of Escherichia coli. Appl. Microbiol. Biotechnol. 98: 1237-1246
38. Levy R, Weiss R, Chen G, Iverson BL, Georgiou G. 2001. Production of correctly folded Fab antibody fragment in the cytoplasm of Escherichia coli trxB gor mutants via the coexpression of molecular chaperones. Protein Expr. Purif. 23: 338-347
39. Linder P, Daugeron M-C. 2000. Are DEAD-box proteins becoming respectable helicases? Nat. Struct. Biol. 7: 97-99
40. Maeng BH, Nam DH, Kim YH. 2011. Coexpression of molecular chaperones to enhance functional expression of anti-BNPscFv in the cytoplasm of Escherichia coli for the detection of B-type natriuretic peptide. World J. Microbiol. Biotechnol. 27: 1391-1398
41. Makrides SC. 1996. Strategies for achieving high-level expression of genes in Escherichia coli. Microbiol. Rev. 60: 512-538
42. Mavrangelos C, Thiel M, Adamson PJ, Millard DJ, Nobbs S, Zola H, Nichols IC. 2001. Increased yield and activity of soluble single-chain antibody fragments by combining highlevel expression and the Skp periplasmic chaperonin. Protein Expr. Purif. 23: 289-295
43. McNulty DE, Claffee BA, Huddleston MJ, Kane JF. 2003. Mistranslational errors associated with the rare arginine codon CGG in Escherichia coli. Protein Expr. Purif. 27: 365-374
44. Merritt JH, Ollis AA, Fisher AC, DeLisa MP. 2013. Glycansby-design: engineering bacteria for the biosynthesis of complex glycans and glycoconjugates. Biotechnol. Bioeng. 110: 1550-1564
45. Mohammed Y, El-Baky NA, Redwan NA, Redwan EM. 2012. Expression of human interferon-α8 synthetic gene under P(BAD) promoter. Biochemistry (Mosc.) 77: 1210-1219
46. Mohammed Y, El-Bakym NA, Redwan EM. 2012. Expression, purification, and characterization of recombinant human consensus interferon-alpha in Escherichia coli under λP(L) promoter. Prep. Biochem. Biotechnol. 42: 426-447
47. Nausch H, Huckauf J, Koslowski R, Meyer U, Broer I, Mikschofsky H. 2013. Recombinant production of human interleukin 6 in Escherichia coli. PLoS One 8: e54933
48. Nelson AL, Reichert JM. 2009. Development trends for therapeutic antibody fragments. Nat. Biotechnol. 27: 331-337
49. Newbury SF, Smith NH, Robinson EC, Hiles ID, Higgins CF. 1987. Stabilization of translationally active mRNA by prokaryotic REP sequences. Cell 48: 297-310
50. Nishihara K, Kanemori M, Kitagawa M, Yanagi H, Yura T. 1998. Chaperone coexpression plasmids: differential and synergistic roles of DnaK-DnaJ-GrpE and GroEL-GroES in assisting folding of an allergen of Japanese cedar pollen, Cryj2, in Escherichia coli. Appl. Environ. Microbiol. 64: 1694-1699
51. Ollis AA, Zhang S, Fisher AC, DeLisa MP. 2014. Engineered oligosaccharyltransferases with greatly relaxed acceptor-site specificity. Nat. Chem. Biol. 10: 816-822
52. Overton TW. 2014 Recombinant protein production in bacterial hosts. Drug Discov. Today 19: 590-601
53. Ow DSW, Lim DYX, Nissom PM, Camattari A, Wong VVT. 2010. Co-expression of Skp and FkpA chaperones improves cell viability and alters the global expression of stress response genes during scFvD1.3 production. Microb. Cell Fact. 9: 22
54. Papaneophytou CP, Kontopidis G. 2014. Statistical approaches to maximize recombinant protein expression in Escherichia coli: a general review. Protein Expr. Purif. 94: 22-32
55. Park YS, Seo SW, Hwang S, Chu HS, Ahn JH, Kim TW, et al. 2007. Design of 5’-untranslated region variants for tunable expression in Escherichia coli. Biochem. Biophys. Res. Commun. 356: 136-141
56. Parker J. 1989. Errors and alternatives in reading the universal genetics code. Microbiol. Rev. 53: 273-298
57. Poole ES, Brown CM, Tate WP. 1995. The identity of the base following the stop codon determines the efficiency of in vivo translational termination in Escherichia coli. EMBO J. 14: 151-158
58. Reilly DE, Yansura DG. 2010. Production of monoclonal antibodies in E. coli, pp295-308. In Shire SJ, Gombotz W, Bechtold-Peters K, Andya J. (eds). Current Trends in Monoclonal Antibodies Development and Manufacturing. Springer, New York.
59. Redwan EM. 2006. Optimal gene sequence for optimal protein expression in Escherichia coli: principle requirements. Arab. J. Biotechnol. 11: 493-510
60. Redwan EM. 2007. Cumulative updating of approved biopharmaceuticals. Hum. Antibodies 16: 137-158
61. Redwan EM, Matar SM, El-Aziz GA, Serour EA. 2008. Synthesis of the human insulin gene: protein expression, scaling up and bioactivity. Prep. Biochem. Biotechnol. 38: 24-39
62. Ringquist S, Shinedling S, Barrick D, Green L, Binkley J, Stormo GD, Gold L. 1992. Translation initiation in Escherichia coli: sequences within the ribosome-binding site. Mol. Microbiol. 6: 1219-1229
63. Rodriguez V, Asenjo JA, Andrews BA. 2014. Design and implementation of a high yield production system for recombinant expression of peptides. Microb. Cell Fact. 13: 65
64. Ronez F, Arbault P, Guzzo J. 2012. Co-expression of the small heat shock protein, Lo18, with β-glucosidase in Escherichia coli improves solubilization and reveals various associations with overproduced heterologous protein, GroEL/ ES. Biotechnol. Lett. 34: 935-939
65. Sahdev S, Khattar SK, Saini KS. 2008. Production of active eukaryotic proteins through bacterial expression systems: a review of the existing biotechnology strategies. Mol. Cell. Biochem. 307: 249-264
66. Sanchez JC, Padron G, Santana H, Herrera L. 1998. Elimination of an HuIFN alpha 2b readthrough species, produced in Escherichia coli, by replacing its natural translation stop signal. J. Biotechnol. 63: 179-186
67. Seetharam R, Heeren RA, Wong EY, Braford SR, Klein BK, Aykent S, et al. 1988. Mistranslation in IGF-1 during overexpression of the protein in Escherichia coli using a synthetic gene containing low frequency codons. Biochem. Biophys. Res. Commun. 155: 518-523
68. Seo SW, Yang JS, Cho HS, Yang J, Kim SC, Park JM, et al. 2014. Predictive combinatorial design of mRNA translation initiation regions for systematic optimization of gene expression levels. Sci. Rep. 4: 4515
69. Sørensen HP, Laursen BS, Mortensen KK, Sperling-Petersen HU. 2002. Bacterial translation initiation — mechanism and regulation. Recent Res. Dev. Biophys. Biochem. 2: 243-270
70. Sørensen HP, Sperling-Petersen HU, Mortensen KK. 2003. A favorable solubility partner for the recombinant expression of streptavidin. Protein Expr. Purif. 32: 252-259
71. Sørensen HP, Sperling-Petersen HU, Mortensen KK. 2003. Dialysis strategies for protein refolding: preparative streptavidin production. Protein Expr. Purif. 31: 149-154
72. Sorensen HP, Mortensen KK. 2005. Soluble expression of recombinant proteins in the cytoplasm of Escherichia coli. Microb. Cell Fact. 4: 1
73. Sprengart ML, Porter AG. 1997. Functional importance of RNA interactions in selection of translation initiation codons. Mol. Microbiol. 24: 19-28
74. Stenstrom C, Jin H, Major L, Tate W, Isaksson LA. 2001. Codon bias at the 3’-side of the initiation codon is correlated with translation initiation efficiency in Escherichia coli. Gene 263: 273-284
75. Tegel H, Tourle S, Ottosson J, Persson A. 2010. Increased levels of recombinant human proteins with the Escherichia coli strain Rosetta (DE3). Protein Expr. Purif. 69: 159-167
76. Terra VS, Mills DC, Yates LE, Abouelhadid S, Cuccui J, Wren BW. 2012. Recent developments in bacterial protein glycan coupling technology and glycoconjugate vaccine design. J. Med. Microbiol. 61: 919-926
77. Valderrama-Rincon JD, Fisher AC, Merritt JH, Fan YY, Reading CA, Chhiba K, et al. 2012. An engineered eukaryotic protein glycosylation pathway in Escherichia coli. Nat. Chem. Biol. 8: 434-436
78. Valente CA, Prazeres DMF, Cabral JMS, Monteriro GA. 2004. Translation feature of human alpha 2b interferon production in Escherichia coli. Appl. Environ. Microbiol. 70: 5033-5036
79. Vasina JA, Baneyx F. 1997. Expression of aggregation prone recombinant proteins at low temperatures: a comparative study of the Escherichia coli cspA and tac promoters systems. Protein Expr. Purif. 9: 211-218
80. Voulgaridou GP, Mantso T, Chlichlia K, Panayiotidis MI, Pappa A. 2013. Efficient E. coli expression strategies for production of soluble human crystallin ALDH3A1. Plos One 8: e56582
81. Wacker M, Linton D, Hitchen PG, Nita-Lazar M, Haslam SM, North SJ, et al. 2002. N-linked glycosylation in Campylobacter jejuni and its functional transfer into E. coli. Science 298: 1790-1793
82. Walsh G, Jefferis R. 2006. Post-translational modifications in the context of therapeutic proteins. Nat. Biotechnol. 24: 1241-1252
83. Wetter M, Kowarik M, Steffen M, Carranza P, Corradin G, Wacker M. 2013. Engineering, conjugation, and immunogenicity assessment of Escherichia coli O121 O antigen for its potential use as a typhoid vaccine component. Glycoconj. J. 30: 511-522
84. Yan X, Hu S, Guan Y X, Yao S J. 2012. Coexpression of chaperonin GroEL/GroES markedly enhanced soluble and functional expression of recombinant human interferongamma in Escherichia coli. Appl. Microbiol. Biotechnol. 93: 1065-1074
85. Yarian C, Marszalek M, Sochacka E, Malkiewicz A, Guenther R, Miskiewicz A, Agris PF. 2000. Modified nucleoside dependent Watson-Crick and wobble codon binding by tRNALysUUU species. Biochemistry 39: 13390-13395
86. Yim S, Jeong K, Chang H, Lee S. 2001. High-level secretory production of human granulocytes-colony stimulating factor by fed-batch culture of recombinant Escherichia coli. Bioprocess Biosyst. Eng. 24: 249-254.